Evaluation of an injectable bone substitute (betaTCP/hydroxyapatite/hydroxy-propyl-methyl-cellulose) in severely osteopenic and aged rats.
The use of injectable biomaterials is of interest in osteoporotic patients to locally restore bone mass in sites at risk of fracture. An injectable bone substitute (IBS1 made of betaTCP/hydroxyapatite as a calcium phosphate substitute and hydroxy-propyl-methyl-cellulose as a polymer carrier) was used in a severely osteopenic rat model obtained by combining orchidectomy (ORX) and disuse (paralysis induced by botulinum toxin - BTX). Fifty-six aged male rats were randomized into three groups: 18 were SHAM operated; 38 were ORX and BTX injected in the right hindlimb; they constituted the OP (osteoporotic) group. One month after ORX-BTX surgery, 20 of these OP rats received a IBS1 injection in the right femur (OP-IBS1 rats). Animals were studied at the time of IBS1 injection 1 month post ORX-BTX (M1), 1 month (M2) and 2 months (M3) after IBS1 injection. Bone mass (BV/TV) and microarchitectural parameters were measured by microCT. BV/TV was decreased after ORX-BTX; ORX and BTX had cumulative effects on bone loss (differences maximized on the right femur). BV/TV (combining the volume of both bone and material in OP-IBS1 rats) was elevated at M1 but decreased at M2. Marked bone formation was found onto the biomaterial granules but bone had a woven texture. A marked increase in the number of nonosteoclastic TRAcP+ cells was found in the implanted area. IBS1 induced new bone formation shortly after implantation but both IBS1 and woven bone were resorbed without inducing lamellar bone. Biomaterial trials must be conducted with long-term implantation periods, in aged osteoporotic animals.
Blouin
S
S
INSERM, EMI 0335 - LHEA, Faculté de Médecine, 49045 ANGERS Cedex, France.
Moreau
M F
MF
Weiss
P
P
Daculsi
G
G
Baslé
M F
MF
Chappard
D
D
D000375:Aging; D000818:Animals; D018786:Bone Substitutes / Q000008:administration & dosage; D004195:Disease Models, Animal; D017886:Durapatite; D065347:Hypromellose Derivatives; D015552:Injections, Intralesional; D008297:Male; D008747:Methylcellulose / Q000031:analogs & derivatives*; D010024:Osteoporosis / Q000503:physiopathology / Q000628:therapy*; D051381:Rats; D017208:Rats, Wistar; D012720:Severity of Illness Index
D018786:Bone Substitutes; D065347:Hypromellose Derivatives; D008747:Methylcellulose; D017886:Durapatite